SPIKE-1 TRIAL Trial to test use of potential virus-blocking treatment in improving COVID-19 outcomes

The University of Edinburgh and Cancer Research UK to conduct a trial to test use of potential virus-blocking treatment in improving COVID-19 outcomes

Research title

SPIKE-1 Trial; A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

Research organisation

• The University of Edinburgh
• Cancer Research UK (Trial sponsor)
• Latus Therapeutics Ltd

Researchers:

Principal Investigator:

• Professor Kev Dhaliwal, University of Edinburgh

Co-investigators:

• Prof Bruce Guthrie, The University of Edinburgh
• Prof Brian McKinstry, The University of Edinburgh
• Prof John Norrie, The University of Edinburgh
• Prof Daniel Anthony, University of Oxford
• Prof Grant Churchill, University of Oxford
• Dr Bobojon Nazarov, University of Oxford & Latus Therapeutics
• Dr Colin Ferrett, Oxford University Hospitals NHSFT
• Dr Suzie Anthony, Oxford University Hospitals NHSFT
• Dr Emma Ladds, University of Oxford, Primary Care

FULL ARTICLE HERE:

Photo by SJ Objio on Unsplash